drugset / Trial / NCT05652283
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.
Timeline
- Start
- 2022-11-06
- Primary completion
- 2027-03
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamiparib | Small molecule | 40 mg | Oral |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |